Following an application from BIO SERAE submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of NeOpuntia® on blood lipid parameters associated with cardiovascular risks, especially HDL-cholesterol (Question No EFSA-Q-2008-214) [The EFSA Journal (2008) 788, 1-2.]. The claim proposed by the applicant was worded as follows: ‘NeOpuntia® helps to improve blood lipid parameters associated with cardiovascular risks, especially the HDL-cholesterol’.
Recital 23, Commission Regulation (EC) No 983/2009 of 21 October 2009 on the authorisation and refus…
In forcesince 21 Oct 2009